USD
+$0.00
(+0.00%
)At Close (As of Nov 28, 2025)
$1.46B
Market Cap
28.36
P/E Ratio
1.63
EPS
$48.18
52 Week High
$23.23
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $377M |
| Total Revenue | $631M |
| Cost Of Revenue | $254M |
| Costof Goods And Services Sold | $254M |
| Operating Income | $170M |
| Selling General And Administrative | $172M |
| Research And Development | $0 |
| Operating Expenses | $207M |
| Investment Income Net | - |
| Net Interest Income | -$60M |
| Interest Income | $14M |
| Interest Expense | $74M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $169M |
| Income Before Tax | $99M |
| Income Tax Expense | $29M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $69M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $173M |
| Ebitda | $342M |
| Net Income | $69M |
| Field | Value (USD) |
|---|---|
| Total Assets | $1.7B |
| Total Current Assets | $482M |
| Cash And Cash Equivalents At Carrying Value | $71M |
| Cash And Short Term Investments | $71M |
| Inventory | $36M |
| Current Net Receivables | $229M |
| Total Non Current Assets | $1.2B |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $891M |
| Intangible Assets Excluding Goodwill | $891M |
| Goodwill | $162M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $92M |
| Other Current Assets | $55M |
| Other Non Current Assets | - |
| Total Liabilities | $1.4B |
| Total Current Liabilities | $510M |
| Current Accounts Payable | $3.9M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $66M |
| Total Non Current Liabilities | $925M |
| Capital Lease Obligations | $6.8M |
| Long Term Debt | $788M |
| Current Long Term Debt | $65M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $859M |
| Other Current Liabilities | $425M |
| Other Non Current Liabilities | $1.2M |
| Total Shareholder Equity | $229M |
| Treasury Stock | - |
| Retained Earnings | -$164M |
| Common Stock | $40K |
| Common Stock Shares Outstanding | $40M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $205M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $169M |
| Capital Expenditures | $1.7M |
| Change In Receivables | - |
| Change In Inventory | $14M |
| Profit Loss | - |
| Cashflow From Investment | -$288M |
| Cashflow From Financing | -$61M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$60M |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $69M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $377M |
| Total Revenue | $631M |
| Cost Of Revenue | $254M |
| Costof Goods And Services Sold | $254M |
| Operating Income | $170M |
| Selling General And Administrative | $172M |
| Research And Development | $0 |
| Operating Expenses | $207M |
| Investment Income Net | - |
| Net Interest Income | -$60M |
| Interest Income | $14M |
| Interest Expense | $74M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $169M |
| Income Before Tax | $99M |
| Income Tax Expense | $29M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $69M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $173M |
| Ebitda | $342M |
| Net Income | $69M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Collegium Pharmaceutical, Inc. is a specialized pharmaceutical company headquartered in Stoughton, Massachusetts, focused on developing and commercializing innovative solutions for pain management. The company offers a diverse portfolio of proprietary drug formulations tailored to address a range of pain-related conditions, reflecting its commitment to improving patient outcomes. With a strategic emphasis on enhancing the quality of care within the pain management landscape, Collegium is well-positioned for continued growth and leadership in the specialty pharmaceutical sector, attracting interest from institutional investors seeking to capitalize on advancements in this critical area of healthcare.